In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients.
CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer.
Lead author Dr. Arjun Sahgal, deputy chief of radiation oncology at the Sunnybrook Health Sciences Centre of the University of Toronto, presented the findings from the CCTG SC24 at the American Society for Radiation Oncology (ASTRO) Annual Meeting last week. This randomized phase II/III trial is the first to show that stereotactic body radiation therapy is superior to conventional radiation treatments in alleviating pain from spinal metastases.
The Canadian Cancer Society (CCS) is seeking your input on the development of a new CCS Research Strategy.
As a cancer researcher, CCS is interested in your thoughts about the values, challenges, strengths, and opportunities related to cancer research. This input will inform CCS's cancer research strategy development so that we can be as relevant, supportive and effective as possible with our research funding.
The Canadian Cancer Society Awards for Excellence in Cancer Research recognize individuals who have made, and are making, valuable contributions to the cancer research ecosystem in Canada. Recipients are leaders in their fields who exemplify excellence in science and outstanding service to the scientific community. There are two new awards this year find out more here.
Published: November 04, 2020
Publication for CCTG CO17
Loree JM, Dowers A, Tu D, Jonker D, Edelstein DL, Quinn H, Holtrup F, Price T, Zalcberg JR, Moore MJ, Karapetis CS, Callaghan CJ, Waring P, Kennecke HF, Hamilton SR, Kopetz S. Expanded low allele frequency RAS and BRAF V600E testing in metastatic colorectal cancer as predictive biomarkers for cetuximab in the randomized CO.17 trial (ONLINE). Clin Cancer Res clincanres, 2020.
Congratulations to Dr. Annette Hay, a Senior Investigator with the Canadian Cancer Trials Group and Dr. Matthew Cheung, Hematologist at Sunnybrook Health Sciences Centre. Together they received $100,000 in bridge funding in the Canadian Institutes of Health Research (CIHR) Spring 2020 competition.